Search
ASCO 2026: Known for its leadership in antibody-drug conjugates, Daiichi Sankyo's US CEO and new Head of Global R&D discuss ASCO data and investments it will be making throughout oncology
Ken Keller and John Tsai describe which other modalities besides ADCs that Daiichi thinks about, and cover ASCO and pipeline progress on Enhertu (Her2), Datroway (Trop2), the company's B7-H3.
1 hour ago
ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging
Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new...
Jun 2, 2025
Daiichi Sankyo's leadership comments on DESTINY-Breast06 at #ASCO24
Global Head of Oncology Ken Keller and Chief Operating Officer Hiroyuki Okuzawa describe the significance of today's data and also...
Jun 2, 2024
A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller
Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer.
Jan 10, 2024
.png){kind=logo}
